{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:37:58Z","timestamp":1791909478992,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"DOI":"10.7759\/cureus.30214","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T07:18:25Z","timestamp":1665559105000},"source":"Crossref","is-referenced-by-count":22,"title":["Potential Therapeutic Effects of Psilocybin: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Dev B","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Zilate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols DE","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017, 101:209-19. 10.1002\/cpt.557","journal-title":"Clin Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff CM","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, et al.. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020, 177:391-410. 10.1176\/appi.ajp.2019.19010035","journal-title":"Am J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017, 42:2105-13. 10.1038\/npp.2017.84","journal-title":"Neuropsychopharmacology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg SB","year":"2020","unstructured":"Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020, 284:112749. 10.1016\/j.psychres.2020.112749","journal-title":"Psychiatry Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe H","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, et al.. The therapeutic potential of psilocybin. Molecules. 2021, 26:2948. 10.3390\/molecules26102948","journal-title":"Molecules"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis","volume":"296","author":"Li NX","year":"2022","unstructured":"Li NX, Hu YR, Chen WN, Zhang B. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord. 2022, 296:26-34. 10.1016\/j.jad.2021.09.041","journal-title":"J Affect Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers KP","year":"2020","unstructured":"Kuypers KP. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020, 10:2045125320950567. 10.1177\/2045125320950567","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson MW","year":"2017","unstructured":"Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017, 14:734-40. 10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer MC","year":"2016","unstructured":"Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016, 3:481-8. 10.1016\/S2215-0366(15)00576-3","journal-title":"Lancet Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15540","article-title":"Molecular insights into psychedelic drug action","volume":"162","author":"Slocum ST","year":"2022","unstructured":"Slocum ST, DiBerto JF, Roth BL. Molecular insights into psychedelic drug action. J Neurochem. 2022, 162:24-38. 10.1111\/jnc.15540","journal-title":"J Neurochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00877-y","article-title":"Molecular mechanisms of psilocybin and implications for the treatment of depression","volume":"36","author":"Ling S","year":"2022","unstructured":"Ling S, Ceban F, Lui LM, et al.. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022, 36:17-30. 10.1007\/s40263-021-00877-y","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez JF","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018, 36:45-73. 10.1007\/7854_2017_478","journal-title":"Curr Top Behav Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00224","article-title":"Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review","volume":"11","author":"Heuschkel K","year":"2020","unstructured":"Heuschkel K, Kuypers KP. Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Front Psychiatry. 2020, 11:224. 10.3389\/fpsyt.2020.00224","journal-title":"Front Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley TD","year":"2022","unstructured":"McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022, 21:463-73. 10.1038\/s41573-022-00421-7","journal-title":"Nat Rev Drug Discov"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira RJ","year":"2017","unstructured":"Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017, 49:84-91. 10.1080\/03602532.2016.1278228","journal-title":"Drug Metab Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross S","year":"2018","unstructured":"Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018, 30:317-30. 10.1080\/09540261.2018.1482261","journal-title":"Int Rev Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3928\/02793695-20210816-01","article-title":"Treatment-resistant depression: approaches to treatment","volume":"59","author":"Kverno KS","year":"2021","unstructured":"Kverno KS, Mangano E. Treatment-resistant depression: approaches to treatment. J Psychosoc Nurs Ment Health Serv. 2021, 59:7-11. 10.3928\/02793695-20210816-01","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2016.08.010","article-title":"Return of the psychedelics: psilocybin for treatment resistant depression","volume":"24","author":"Patra S","year":"2016","unstructured":"Patra S. Return of the psychedelics: psilocybin for treatment resistant depression. Asian J Psychiatr. 2016, 24:51-2. 10.1016\/j.ajp.2016.08.010","journal-title":"Asian J Psychiatr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.17.1110","article-title":"Psychedelic drugs in the treatment of anxiety, depression and addiction","volume":"138","author":"Kvam TM","year":"2018","unstructured":"Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskr Nor Laegeforen. 2018, 138:3-7. 10.4045\/tidsskr.17.1110","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090331","article-title":"Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials","volume":"8","author":"Vargas AS","year":"2020","unstructured":"Vargas AS, Lu\u00eds \u00c2, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Biomedicines. 2020, 8:331. 10.3390\/biomedicines8090331","journal-title":"Biomedicines"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz MP","year":"2016","unstructured":"Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016, 64:250-8. 10.1016\/j.pnpbp.2015.03.002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1220834","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"de Veen BT","year":"2017","unstructured":"de Veen BT, Schellekens AF, Verheij MM, Homberg JR. Psilocybin for treating substance use disorders?. Expert Rev Neurother. 2017, 17:203-12. 10.1080\/14737175.2016.1220834","journal-title":"Expert Rev Neurother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173129","article-title":"Use and abuse of dissociative and psychedelic drugs in adolescence","volume":"203","author":"Bates ML","year":"2021","unstructured":"Bates ML, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021, 203:173129. 10.1016\/j.pbb.2021.173129","journal-title":"Pharmacol Biochem Behav"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1055\/a-1341-1907","article-title":"Classical psychedelics as therapeutics in psychiatry - current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders","volume":"54","author":"Mertens LJ","year":"2021","unstructured":"Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry - current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry. 2021, 54:176-90. 10.1055\/a-1341-1907","journal-title":"Pharmacopsychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1826931","article-title":"The emerging role of psilocybin and MDMA in the treatment of mental illness","volume":"20","author":"Gill H","year":"2020","unstructured":"Gill H, Gill B, Chen-Li D, et al.. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2020, 20:1263-73. 10.1080\/14737175.2020.1826931","journal-title":"Expert Rev Neurother"},{"key":"ref27","article-title":"Addictions (Article in French)","volume":"16","author":"Vogel M","year":"2020","unstructured":"Vogel M, Strasser H, Thorens G, et al.. Addictions (Article in French). Rev Med Suisse. 2020, 16:8-11.","journal-title":"Rev Med Suisse"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12636","article-title":"Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives","volume":"35","author":"Courault P","year":"2021","unstructured":"Courault P, Demarquay G, Zimmer L, Lancelot S. Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives. Fundam Clin Pharmacol. 2021, 35:595-619. 10.1111\/fcp.12636","journal-title":"Fundam Clin Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin--summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161 F","year":"2014","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Hor\u00e1\u010dek J. Psilocybin--summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014, 24:342-56. 10.1016\/j.euroneuro.2013.12.006","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine","volume":"41","author":"De Gregorio D","year":"2021","unstructured":"De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci. 2021, 41:891-900. 10.1523\/JNEUROSCI.1659-20.2020","journal-title":"J Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110369-potential-therapeutic-effects-of-psilocybin-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:50:17Z","timestamp":1707490217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110369-potential-therapeutic-effects-of-psilocybin-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.30214","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}